Journal of Natural Medicines

, Volume 66, Issue 1, pp 8–16 | Cite as

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells

  • Ji-Won Lee
  • Ayumi Iwahashi
  • Shin-ichi Hasegawa
  • Takayuki Yonezawa
  • Won Bae Jeon
  • Byung-Yoon Cha
  • Kazuo Nagai
  • Je-Tae Woo
Original Paper


Excessive receptor activator of NF-κB ligand (RANKL) signaling causes enhanced osteoclast formation and bone resorption. The downregulation of RANKL expression and its downstream signals may be an effective therapeutic approach to the treatment of bone loss diseases such as osteoporosis. Here, we found that coptisine, one of the isoquinoline alkaloids from Coptidis Rhizoma, exhibited inhibitory effects on osteoclastogenesis in vitro. Although coptisine has been studied for its antipyretic, antiphotooxidative, dampness dispelling, antidote, antinociceptive, and anti-inflammatory activities in vitro and in vivo, its effects on osteoclastogenesis have not been investigated. Therefore, we evaluated the effects of coptisine on osteoblastic cells as well as osteoclast precursors for osteoclastogenesis in vitro. The addition of coptisine to cocultures of mouse bone marrow cells and primary osteoblastic cells with 10−8 M 1α,25(OH)2D3 caused significant inhibition of osteoclast formation in a dose-dependent manner. Reverse transcriptase polymerase chain reaction (RT-PCR) analyses revealed that coptisine inhibited RANKL gene expression and stimulated the osteoprotegerin gene expression induced by 1α,25(OH)2D3 in osteoblastic cells. Coptisine strongly inhibited RANKL-induced osteoclast formation when added during the early stage of bone marrow macrophage (BMM) cultures, suggesting that it acts on osteoclast precursors to inhibit RANKL/RANK signaling. Among the RANK signaling pathways, coptisine inhibited NF-κB p65 phosphorylations, which are regulated in response to RANKL in BMMs. Coptisine also inhibited the RANKL-induced expression of NFATc1, which is a key transcription factor. In addition, 10 μM coptisine significantly inhibited both the survival of mature osteoclasts and their pit-forming activity in cocultures. Thus, coptisine has potential for the treatment or prevention of several bone diseases characterized by excessive bone destruction.


Coptisine RANKL Osteoclast NFATc1 



This study was supported by a grant for Bio-Defense Programs from the Ministry of Education, Science and Technology (MEST) of the Republic of Korea.

Conflict of interest

The authors have no conflicts of interest.


  1. 1.
    Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251–264PubMedCrossRefGoogle Scholar
  2. 2.
    Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors. J Exp Med 190:1741–1754PubMedCrossRefGoogle Scholar
  3. 3.
    Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342PubMedCrossRefGoogle Scholar
  4. 4.
    Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2–12PubMedCrossRefGoogle Scholar
  5. 5.
    Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478–3484PubMedCrossRefGoogle Scholar
  6. 6.
    Takahashi N, Udagawa N, Kobayashi Y, Suda T (2007) Generation of osteoclasts in vitro, and assay of osteoclast activity. Methods Mol Med 135:285–301PubMedCrossRefGoogle Scholar
  7. 7.
    Teitelbaum SL (2004) RANKing c-Jun in osteoclast development. J Clin Invest 114:463–465PubMedGoogle Scholar
  8. 8.
    Phillipson JD, Anderson LA (1989) Ethnopharmacology and Western medicine. J Ethnopharmacol 25:61–72PubMedCrossRefGoogle Scholar
  9. 9.
    Li H, Miyahara T, Tezuka Y, Namba T, Nemoto N, Tonami S, Seto H, Tada T, Kadota S (1998) The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan. Biol Pharm Bull 21:1322–1326PubMedCrossRefGoogle Scholar
  10. 10.
    Sun J, Ma JS, Jin J, Wang HS, Wen QH, Zhang HG, Zhou QL (2006) Qualitative and quantitative determination of the main components of huanglianjiedu decoction by HPLC-UV/MS. Yao Xue Xue Bao 41:380–384PubMedGoogle Scholar
  11. 11.
    Tang LQ, Wei W, Chen LM, Liu S (2006) Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 108:109–115PubMedCrossRefGoogle Scholar
  12. 12.
    Kuo CL, Chi CW, Liu TY (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203:127–137PubMedCrossRefGoogle Scholar
  13. 13.
    Yokozawa T, Satoh A, Cho EJ, Kashiwada Y, Ikeshiro Y (2005) Protective role of Coptidis Rhizoma alkaloids against peroxynitrite-induced damage to renal tubular epithelial cells. J Pharm Pharmacol 57:367–374PubMedCrossRefGoogle Scholar
  14. 14.
    Tan B, Ma Y, Shi R, Wang T (2007) Simultaneous quantification of three alkaloids of Coptidis Rhizoma in rat urine by high-performance liquid chromatography: application to pharmacokinetic study. Biopharm Drug Dispos 28:511–516PubMedCrossRefGoogle Scholar
  15. 15.
    Li HL, Zhang WD, Liu RH, Zhang C, Han T, Wang XW, Wang XL, Zhu JB, Chen CL (2006) Simultaneous determination of four active alkaloids from a traditional Chinese medicine Corydalis saxicola Bunting. (Yanhuanglian) in plasma and urine samples by LC-MS-MS. J Chromatogr B Analyt Technol Biomed Life Sci 831:140–146PubMedCrossRefGoogle Scholar
  16. 16.
    Qin L, Han T, Zhang Q, Cao D, Nian H, Rahman K, Zheng H (2008) Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. J Ethnopharmacol 23:271–279CrossRefGoogle Scholar
  17. 17.
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357PubMedCrossRefGoogle Scholar
  18. 18.
    Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304PubMedCrossRefGoogle Scholar
  19. 19.
    Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24:33–63PubMedCrossRefGoogle Scholar
  20. 20.
    Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U (1997) Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 11:3482–3496PubMedCrossRefGoogle Scholar
  21. 21.
    Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 3:1285–1289PubMedCrossRefGoogle Scholar
  22. 22.
    Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T, Okamoto K (2008) Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-κB and Akt pathways. Eur J Pharmacol 580:70–79PubMedCrossRefGoogle Scholar
  23. 23.
    Chang EJ, Kim HJ, Ha J, Kim HJ, Ryu J, Park KH, Kim UH, Lee ZH, Kim HM, Fisher DE, Kim HH (2007) Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci 120:166–176PubMedCrossRefGoogle Scholar
  24. 24.
    Chambers TJ, Magnus CJ (1982) Calcitonin alters behaviour of isolated osteoclasts. J Pathol 136:27–39PubMedCrossRefGoogle Scholar
  25. 25.
    Väänänen HK, Zhao H, Mulari M, Halleen JM (2000) The cell biology of osteoclast function. J Cell Sci 113:377–381PubMedGoogle Scholar
  26. 26.
    Destaing O, Saltel F, Géminard JC, Jurdic P, Bard F (2003) Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein. Mol Biol Cell 14:407–416PubMedCrossRefGoogle Scholar
  27. 27.
    Saltel F, Destaing O, Bard F, Eichert D, Jurdic P (2004) Apatite-mediated actin dynamics in resorbing osteoclasts. Mol Biol Cell 15:5231–5241PubMedCrossRefGoogle Scholar
  28. 28.
    Lakkakorpi PT, Väänänen HK (1990) Calcitonin, prostaglandin E2, and dibutyryl cyclic adenosine 3′,5′-monophosphate disperse the specific microfilament structure in resorbing osteoclasts. J Histochem Cytochem 38:1487–1493PubMedCrossRefGoogle Scholar
  29. 29.
    Nakamura I, Takahashi N, Sasaki T, Tanaka S, Udagawa N, Murakami H, Kimura K, Kabuyama Y, Kurokawa T, Suda T, Yasuhisa F (1995) Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption. FEBS Lett 361:79–84PubMedCrossRefGoogle Scholar
  30. 30.
    Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y, Hori M, Suda T (1996) Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology 137:4685–4690PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Pharmacognosy and Springer 2011

Authors and Affiliations

  • Ji-Won Lee
    • 1
  • Ayumi Iwahashi
    • 1
  • Shin-ichi Hasegawa
    • 1
  • Takayuki Yonezawa
    • 1
  • Won Bae Jeon
    • 2
  • Byung-Yoon Cha
    • 1
  • Kazuo Nagai
    • 1
    • 3
  • Je-Tae Woo
    • 1
    • 3
  1. 1.Research Institute for Biological FunctionsChubu UniversityKasugaiJapan
  2. 2.Daegu Gyeongbuk Institute of Science and TechnologyDaeguRepublic of Korea
  3. 3.Department of Biological ChemistryChubu UniversityKasugaiJapan

Personalised recommendations